Article: FOSAMAX Once-Weekly U.S. Patent Upheld.

Business Editors/Health/Medical Writers

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Aug. 28, 2003

Merck & Co., Inc. announced today that the U.S. District Court in Wilmington, Del., upheld Merck's U.S. patent covering the weekly administration of FOSAMAX(R) (alendronate sodium) Once-Weekly. As a result of the court's decision, the patent is valid and infringed by Teva Pharmaceuticals USA, Inc.'s Abbreviated New Drug Application (ANDA) filing. Merck filed a patent infringement lawsuit against Teva in January 2001. The FOSAMAX Once-Weekly patent expires in July 2018. The court's decision is subject to appeal.

FOSAMAX is the world's leading ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!